Sedana Medical publishes Annual Report 2021
Sedana Medical AB (publ) (SEDANA: FN Stockholm) published its Annual Report 2021.In addition to significant events and financial information of 2021, the Annual Report focuses on the strategic priorities and ambitions to introduce inhaled sedation to intensive care. “In 2021, we delivered the highest turnover in our history and made strong progress on both of our main priorities: to execute an excellent launch of Sedaconda (isoflurane) in Europe and to prepare for the important US market”, said Johannes Doll, CEO of Sedana Medical. The Annual Report is available at www.sedanamedical.